A pregnant client at 28 weeks gestation with HIV infection comes to the prenatal clinic for routine follow-up. The nurse is reviewing the client's laboratory results. Which laboratory finding would be the most critical for the nurse to assess and report immediately to the healthcare provider?

CD4+ T-cell count of 180 cells/mm³ indicates severe immunosuppression, requiring immediate intervention to prevent opportunistic infections and optimize maternal-fetal outcomes. Other lab values are within normal or expected ranges for pregnancy.

Understanding the Clinical Priority

When caring for a pregnant client at 28 weeks gestation with HIV, the nurse must interpret laboratory values within the context of both the pregnancy-related physiological changes and the pathophysiology of HIV. While several values may fall outside standard non-pregnant reference ranges, the immediate clinical priority is identifying a result that signals a severe immunocompromised state, which directly threatens maternal health and increases the risk of vertical transmission.

Analysis of Laboratory Findings

1. Hemoglobin level of 10.2 g/dL: This value represents a mild physiological anemia of pregnancy, a common finding in the second and third trimesters due to hemodilution. While it requires monitoring, it is not an acute, critical finding in this context.
2. White blood cell count of 4,500/mm³: This value falls at the lower end of the normal range. A mild leukopenia can be associated with HIV infection, but this level does not represent an immediate emergency.
3. CD4+ T-cell count of 180 cells/mm³: This is the most critical finding. A CD4+ T-cell count below 200 cells/mm³ is a defining criterion for a diagnosis of Acquired Immunodeficiency Syndrome (AIDS) in an HIV-positive individual, regardless of the presence of opportunistic infections. This profound immunosuppression places the client at severe risk for opportunistic infections and is a major determinant for maternal disease progression and perinatal transmission risk. The evidence confirms that CD4 count is a central clinical marker directly linked to maternal outcomes and the risk of vertical transmission . A count this low necessitates an immediate and aggressive review of the antiretroviral therapy (ART) regimen and prophylaxis against opportunistic infections.
4. Platelet count of 150,000/mm³: This value is at the lower boundary of the normal range. Mild thrombocytopenia can occur with HIV, but this level does not typically pose an immediate risk for spontaneous bleeding and is not the most critical finding.

The Critical Role of the CD4 Count in Pregnancy and HIV

The CD4+ T-cell count is the primary immunologic marker used to assess the degree of immune system damage caused by HIV. A result of 180 cells/mm³ indicates a severely weakened immune system. The clinical significance is twofold. First, for the mother, this level of immunosuppression dramatically elevates the risk for life-threatening opportunistic infections such as Pneumocystis jirovecii pneumonia. Second, for the fetus, a low maternal CD4 count is a well-established independent risk factor for mother-to-child transmission (MTCT) of HIV. The foundational principle of the Option B+ policy, which mandates lifelong ART for all pregnant women, was specifically designed to address this risk by initiating treatment irrespective of CD4 count, yet the count itself remains a crucial prognostic indicator [2, 4]. A finding this low in a client already on follow-up suggests either a gap in engagement in care, a failure of the current ART regimen, or a recent seroconversion, all of which require urgent intervention. Studies on comprehensive HIV care for women reinforce that CD4 count monitoring, alongside viral load, is fundamental to evaluating treatment efficacy and clinical stability .